1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,640 | 2,800 | 14:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02:34 | Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC | 287 | GlobeNewswire (Europe) | SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| Mo | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF JS001SC FOR THE FIRST-LINE TREATMENT OF NON-SQUAMOUS NSCLC MET PRIMARY ENDPOINTS | - | HKEx | ||
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 14.11. | JUNSHI BIO (01877): COMPLETION OF REGISTRATION OF THE FIRST GRANT OF A SHARE OPTIONS UNDER THE 2025 A SHARE OPTION INCENTIVE SCHEME | - | HKEx | ||
| 10.11. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON PROGRESS OF THE INCREASE IN SHAREHOLDING ... | 1 | HKEx | ||
| 28.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 2025 THIRD QUARTERLY REPORT | 1 | HKEx | ||
| 22.10. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - WHOLLY-OWNED SUBSIDIARY PASSING FDA ON-SITE INSPECTION | 2 | HKEx | ||
| 21.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE CONVENING OF THE 2025 THIRD QUARTERLY ... | 1 | HKEx | ||
| 17.10. | Junshi Biosciences gets FDA approval for lung cancer trial | 2 | Investing.com | ||
| 17.10. | Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients | 396 | GlobeNewswire (Europe) | SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 16.10. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - FDA APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION FOR PHASE II/III CLINICAL STUDY OF JS207 FOR THE NEOADJUVANT ... | - | HKEx | ||
| 15.10. | JUNSHI BIO (01877): DATE OF BOARD MEETING | - | HKEx | ||
| 10.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON PROGRESS OF THE INCREASE IN SHAREHOLDING ... | 1 | HKEx | ||
| 29.09. | JUNSHI BIO (01877): ADJUSTMENTS TO THE LIST OF PARTICIPANTS AND THE NUMBER OF A SHARE OPTIONS TO BE GRANTED AND THE FIRST GRANT OF A SHARE OPTIONS TO ... | 2 | HKEx | ||
| 29.09. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD. ANNOUNCEMENT ON EXTERNAL INVESTMENT AND RELATED PARTY TRANSACTION | 1 | HKEx | ||
| 29.09. | JUNSHI BIO (01877): POLL RESULTS OF THE 2025 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 29.09. | JUNSHI BIO (01877): ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTOR CHANGE IN COMPOSITION OF THE REMUNERATION AND APPRAISAL COMMITTEE AND THE NOMINATION ... | 3 | HKEx | ||
| 29.09. | JUNSHI BIO (01877): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 29.09. | JUNSHI BIO (01877): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 26.09. | JUNSHI BIO (01877): 2025 INTERIM REPORT | - | HKEx | ||
| 25.09. | UBS stuft Shanghai Junshi Biosciences wegen hoher Bewertung auf "Neutral" herab | 3 | Investing.com Deutsch |
1 2 3 4 Weiter >>
73 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCELLX | 74,96 | 0,00 % | Guggenheim bestätigt Kaufempfehlung für Arcellx: Aktuelle Kursschwäche übertrieben | ||
| ARCUTIS BIOTHERAPEUTICS | 30,760 | 0,00 % | Why Shares in Arcutis Biotherapeutics Surged Again This Week | ||
| DISC MEDICINE | 94,11 | 0,00 % | Jefferies bestätigt Kaufempfehlung für Disc Medicine angesichts wichtiger Katalysatoren | ||
| DYNE THERAPEUTICS | 21,670 | 0,00 % | Why Dyne Therapeutics Stock Was Crushing it This Week | ||
| PRAXIS PRECISION MEDICINES | 191,36 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| AVIDITY BIOSCIENCES | 71,18 | 0,00 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| IMMUNOVANT | 23,320 | 0,00 % | Immunovant, Inc. - 8-K, Current Report | ||
| OLEMA PHARMACEUTICALS | 25,055 | 0,00 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| RELAY THERAPEUTICS | 8,170 | 0,00 % | Relay Therapeutics: Citizens bestätigt "Market Outperform"-Rating und Kursziel von 12 US-Dollar | ||
| RAPPORT THERAPEUTICS | 28,320 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,320 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 12,930 | 0,00 % | Vielversprechende AML-Daten: BTIG erhöht Kursziel für Cullinan Oncology auf 38 US-Dollar | ||
| DAY ONE BIOPHARMACEUTICALS | 8,880 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases | Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid... ► Artikel lesen | |
| ARVINAS | 11,770 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,540 | 0,00 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So |
Das Unternehmen SHANGHAI JUNSHI BIOSCIENCES CO LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,060 (+2,34 %) liegt der Kurs bei 2,620 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI JUNSHI BIOSCIENCES CO LTD finden Sie auf Wallstreet Online.